Neurology

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy


In the article “Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy” by Mullin et al.,1 first published online January 13, 2020, the last sentence of the abstract’s Results should read “While using rimegepant alone or together with erenumab, patients reported no related adverse events.” The sentence appears correctly in the May 19, 2020, issue. The authors regret the error.

Source link

Related posts

Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial

Newsemia

Editors' note: Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment

Newsemia

What's happening in Neurology

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World